Josh Bittker directs the lead discovery efforts of the Chemical Biology Platform at the Broad Institute of MIT and Harvard. In this role, he oversees small teams within the platform’s small-molecule high-throughput screening group, which focuses on large-scale efforts to screen small-molecule compounds for a desired effect in cells. The teams address compound management, laboratory automation, analytical chemistry, and high-throughput screening execution.
Under Bittker’s leadership, the groups are responsible for screening several hundred thousand compounds against dozens of targets each year, generating more than 20 million data points. The result of these screens is a series of small-molecule tool compounds, also known as probes, for interrogating different biological systems in the lab. In some cases, outstanding probes have the potential to serve as a starting point for therapeutic development.
Bittker joined the Broad Institute in 2008 after completing a Ph.D. in chemistry from Harvard University.Select Publications
Bittker JA, et al. Screen for RAS-Selective Lethal Compounds and VDAC Ligands. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. 2010 Mar 26 [updated 2011 Feb 10].
Fomina-Yadlin D, et al. Small-molecule inducers of insulin expression in pancreatic alpha-cells. Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15099-104. Epub 2010 Aug 9.
Swamidass SJ, et al. An economic framework to prioritize confirmatory tests after a high-throughput screen. J Biomol Screen. 2010 Jul;15(6):680-6. Epub 2010 Jun 14.